Shares of Peregrine (NAS: PPHM) shot up 28% on Nov. 27, and another 36% on Friday. In this video, Motley Fool health-care analyst Brenton Flynn discusses some of the information management might be reporting on when it makes its quarterly statement on Dec. 10. Investors are awaiting news on several indications for treatment of various types of cancer from the company's drug Bavituximab. The company faced controversy and a share-price tumble recently when it announced that mistakes had been made in the handling of some previous Bavituximab data that left it unclear which trial patients received the drug and which received a placebo, rendering the data useless.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article What's Driving This Biotech Stock Through the Roof? originally appeared on Fool.com.
Brenton Flynn, Max Macaluso, and The Motley Fool have no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.